Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Nektar Therapeutics ( (NKTR) ) has issued an update.
On May 8, 2026, Nektar Therapeutics entered into an equity distribution agreement with Guggenheim Securities and H.C. Wainwright, allowing the company to sell up to $150 million of common stock from time to time through at-the-market and other permitted methods under its existing shelf registration. The flexible structure gives Nektar an additional financing avenue without obligating it or the agents to sell specific amounts, while committing the company to a 3% commission and customary indemnification and expense reimbursements for the agents.
On May 7, 2026, Nektar announced that interim Chief Financial Officer Sandra Gardiner will retire and step down effective May 15, 2026, to be succeeded by fellow FLG Partners executive Linda Rubinstein as interim CFO and principal financial and accounting officer. Rubinstein, a veteran life sciences finance executive with extensive capital markets and M&A experience, will serve under an amended consulting agreement with FLG that provides hourly compensation and indemnification, signaling continuity in outsourced finance leadership during a key capital-raising period.
The most recent analyst rating on (NKTR) stock is a Buy with a $192.00 price target. To see the full list of analyst forecasts on Nektar Therapeutics stock, see the NKTR Stock Forecast page.
Spark’s Take on NKTR Stock
According to Spark, TipRanks’ AI Analyst, NKTR is a Neutral.
The score is held back primarily by weak financial performance (persistent losses and significant cash burn). Offsetting this, the latest earnings call provided strong clinical and execution milestones plus a substantially strengthened cash position and multi-year runway. Technicals are moderately supportive (above longer-term averages with neutral momentum), while valuation remains constrained by loss-making fundamentals and no dividend data.
To see Spark’s full report on NKTR stock, click here.
More about Nektar Therapeutics
Nektar Therapeutics operates in the biopharmaceutical sector, focusing on the development of drug candidates using its proprietary chemistry platforms and technologies. The company accesses capital markets via Nasdaq listings and shelf registrations to fund its research, clinical development, and corporate activities, often partnering with specialized financial intermediaries for securities offerings.
Average Trading Volume: 1,279,917
Technical Sentiment Signal: Buy
Current Market Cap: $2.77B
Learn more about NKTR stock on TipRanks’ Stock Analysis page.